- The United States gets the vast majority of common general drugs from ChinaIn the sense that President Donald Trump’s sharp tariff for Chinese imports can cause major drug shortages. Public medicines at reasonable prices due to the margins of high manufacturers companies. Increased costs as a result of definitions can nullify them from the production of some pain relief.
Definitions already Many Americans care About the state of the economy, but taxes on pharmaceutical commodities from China can offer a more literal headache.
The United States gets all its supplies from common drugs that do not need a prescription from China, which means that President Donald Trump’s tariff by 145 % on the country can have a significant impact on the United States style in identifying the main drugs, and the chief economist Apollo Torrestin extinguishes He said on Wednesday Blog post. About 95 % of ibuprofen in the United States comes from China, SLØNote K, quoting data from the Organization of the Organization for Commercial Protection for the Flooding America and the National Center for National Institutes of Health Technology.
More than 90 % of the anti -inflammatory steroid hydrocortisone supplies come from China, as well as 70 % of acetaminophen and 45 % of penicillin imports in the United States. The United States depends in particular on China More affordable drugsAnd public drugs makeup 90 % of the prescriptions are full In the United States, according to the food and drug administration.
The customs duties have already threatened more broadly Availability of consumer products In the United States where American companies store the goods before the customs duties enter into force, only to back down as soon as these products become more expensive.
“The result will be the empty shelves in American stores within a few weeks and a problem similar to consumers and companies that use Chinese products as intermediate commodities,” said behavior in A. April 25.
According to Los Angeles, the CEO of Los Angeles, the largest port in the United States, who receives about 45 % of his imports from China. Seroka began to see “Arough drop” In China’s shipments, which will lead to five to seven weeks of full stocks on retail shelves, as predicted.
The White House did not respond immediately luckInvestigation on plans to exempt medications from definitions.
A lack of drug shortage
For drug supply in America, tariffs can make a bad problem.
Against the United States with a lack of drugs stubborn in the past three quarters, with 270 active deficiency As of March 2025, but from the highest level of 323 decreased in early 2024, according to the American Pharmacists Association of the Health System. This deficiency It could be caused Natural disasters lead to temporarily stopping production or organizational challenges.
The main players in the pharmaceutical industry will accumulate fear for the factors that drive scarcity. The profit margins of public drugs are incredibly thin to keep them affordable, which means that some manufacturers can stop producing expensive medicines, which makes them a result of increasing the cost of raw materials, according to John Murphy, President and Executive Director of the AAM Trade Group Association (AAM). Murphy said that any hiccups in the supply chain worse, and what makes it worse, will also mean an increase in drug prices for consumers.
“AAM is concerned … that any duties on pharmaceutical products, especially inputs, will increase the costs of manufacturing generational and biological drugs in the United States, and therefore, lead to high prices of prescribed medications and low access to patients in our country,” said Murphy. March message Our commercial actor Jameson Jarir.
Despite Trump’s intention to definitions as encouraging domestic production, American pharmaceutical companies may be hesitant to seize the opportunity to increase their manufacturing capabilities, Marta and Lucisca, a health expert and his colleague at the Brookings Foundation, He said USA today. The future of definitions – with Trump now Consider cutting “great” Officials – He takes off a lot of the inability to predict the pharmaceutical companies to take meaningful steps to address them.
“Investing one billion dollars in the United States when I do not even know whether the definitions will be there a month from now on making it a truly difficult account for companies,” Wucianska said.
This story was originally shown on Fortune.com
https://fortune.com/img-assets/wp-content/uploads/2025/04/GettyImages-2163305242-e1746034653351.jpg?resize=1200,600
Source link